Ask AI
ProCE Banner Activity

Hematologist On Call: Relapsed/Refractory Mantle Cell Lymphoma Post cBTKi

Podcast

In this podcast episode, experts discuss the evolving treatment landscape of R/R mantle cell lymphoma as the use of covalent BTK inhibitors further expands into the first-line setting. The discussion highlights the similarities and differences between small molecules pirtobrutinib and sonrotoclax including patient selection, step-up dosing requirements, TLS monitoring, efficacy post covalent BTKi, sequencing, and the feasibility of implementing treatment in community practices. They also examine the dosing, efficacy, and safety of CAR T-cell therapy and bispecific antibodies, establishing their current and possible future roles in R/R MCL. 

Released: October 20, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from BeOne Medicines.

BeOne Medicines

Target Audience

This activity is intended for hematologist/oncologists, nurse practitioners (NPs), physician associates/assistants (PAs), nurses, pharmacists, and other interprofessional team members involved in the care of patients with R/R MCL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate patient-, disease-, and prior-treatment factors that inform post-cBTKi therapy selection in R/R MCL, including BTKi progression vs intolerance, relapse tempo, tumor burden, TP53 mutation, blastoid/pleomorphic morphology, Ki-67, performance status, comorbidities, access, and patient goals

  • Compare BTK- and BCL2-directed small-molecule strategies and contextualize CAR T-cell and bispecific antibody options using mechanism, efficacy, safety, treatment duration, monitoring needs, and implementation feasibility

  • Apply best practices for therapy-specific safety planning and supportive care, with emphasis on TLS risk assessment and monitoring for BCL2 inhibitor-based therapy, infection/cytopenia mitigation, drug interactions, referral readiness, and patient/caregiver counseling

  • Implement interprofessional, community-relevant care pathways that improve referral timing, shared decision-making, patient/caregiver education, monitoring adherence, and reassessment for patients with R/R MCL after cBTKi exposure

Financial Disclosures

Primary Author

Toby A. Eyre, MD, MBChB: consultant/advisor/speaker: AbbVie, AstraZeneca, Autolus, BeiGene, Galapagos, Gilead, Incyte, Janssen, Kite, Loxo Oncology, Roche; researcher: AstraZeneca, BeiGene, Gilead; other financial or material support: AbbVie, AstraZeneca, Roche.

Tycel J. Phillips, MD, FASCO: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeOne, Bristol Myers Squibb, Caribou, Eli Lilly, Genentech, Gilead, Immunomune,  Incyte, Janssen, Johnson & Johnson, Kite, Legend Biotech, Miltenyi, Pharmacyclics, Regeneron, Sobi, Xencor; researcher: AbbVie, Bristol Myers Squibb, Genentech, Sobi.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content and generating transcripts from audio/video files. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.